Status and phase
Conditions
Treatments
About
To evaluate SGX302 (topical hypericin ointment) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
42 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Christopher Pullion, DO
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal